Nucleoside News and Research

RSS

Nucleoside modifications suppress the potential of RNA to activate dendritic cells

A new paper shows that human TLR3, TLR7, and TLR8 receptors are activated with naturally occurring RNA, but this is eliminated once modified nucleosides such as m5C, m6A, m5U s2U, or pseudouridine are incorporated.

12 Oct 2021

Lipids, COVID-19, and host immunity

A new study from a team of researchers at the University of Pennsylvania examines the role played by lipids in this disease.

10 Oct 2021

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

A recent study assesses the serological and cellular responses to Pfizer’s BNT162b2 mRNA vaccine in people aged 80-96 years.

4 Oct 2021

Difficulties of stability and storage of mRNA COVID-19 vaccines

Two researchers have collaborated to review the difficulties faced in storing and transporting these vaccines in a manner that will keep them stable.

4 Oct 2021

Damaging DNA builds up in the eyes to drive blinding age-related macular degeneration

Damaging DNA builds up in the eyes of patients with geographic atrophy, an untreatable, poorly understood form of age-related macular degeneration that causes blindness, new research from the University of Virginia School of Medicine reveals.

1 Oct 2021

Design of mRNA vaccines to combat COVID-19

A recent review study discusses fundamental concepts in the successful delivery of nucleic acids in therapeutics.

23 Sep 2021

SARS-CoV-2 genome signature leads to replicative advantage in presence of Remdesivir

A new study indicates that low-level resistance of SARS-CoV-2 to remdesivir is not widespread and dissimilar to other RNA viruses revealing evolutionary predictability of this pandemic virus.

22 Sep 2021

Is the Pfizer-BioNTech COVID vaccine still effective after 6 months?

A team of researchers assessed the effectiveness of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine.

21 Sep 2021

Antiviral compound RG10 acts via intracellular SARS-CoV-2-ER dynamics

A new study describes a small molecule referred to as RG10 that may have potent antiviral activity against SARS-CoV-2 in human cells.

16 Sep 2021

A sweet pill to swallow: oral nucleoside analog of Remdesivir improved SARS-CoV-2 pathogenesis in mice

A new study focused on in vitro antiviral activity in various cell models and in vivo therapeutic efficacy of oral GS-621763 in a mouse model of SARS-CoV-2 pathogenesis.

15 Sep 2021

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

In new research, scientists evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2.

10 Aug 2021

BNT162b2 vaccine shows high efficacy at six months

The Pfizer/BioNTech vaccine appears to be highly effective in protecting against the SARS-CoV-2 infection, including its relatively resistant beta variant B.1.351.

30 Jul 2021

Molecular dynamic analysis of SARS-CoV-2 inhibitors

A new study reports the results of molecular dynamic simulations that were performed in an effort to identify new drugs that could be effective against SARS-CoV-2.

13 Jul 2021

SARS-CoV-2 inhibited by pyrimidine biosynthesis inhibitors in conjunction with nucleoside analogs

In an effort to hasten the research on identifying antiviral drugs for SARS-CoV-2 infection, researchers from the U.S. and Switzerland performed extensive drug screening for antiviral activity using live virus infection in human respiratory cells. As a result, they identified a set of possible drug candidates that could potentially be tested in clinical trials.

30 Jun 2021

Study finds no evidence for remdesivir's benefit in severe COVID-19 patients

A new analysis of current data indicates that remdesivir does not show efficacy in regulating the severity of the illness.

23 Jun 2021

Study may offer an unexpected pathway for targeted treatment of brain tumors

In a new study led by Yale Cancer Center, researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier (BBB) and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.

15 Jun 2021

Scientists explain possible causes of anaphylaxis following mRNA COVID-19 vaccination

New research from a team of scientists at the Centre for Research in Molecular Modeling, Department of Chemistry and Biochemistry, Concordia University in Canada, has aimed to determine the potential causes of anaphylaxis or allergic reactions reported in some individuals after receiving COVID-19 vaccines, including the mRNA vaccines by Pfizer-BioNTech and Moderna.

1 Jun 2021

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

Could 6′,6′-difluoro-aristeromycin (DFA) have broad-spectrum antiviral potential against coronaviruses?

Researchers at the Leiden University Medical Center demonstrated that low-micromolar concentrations of 6′,6′-difluoro24 aristeromycin (DFA), an adenosine nucleoside analog, strongly inhibits the replication of Middle East respiratory syndrome coronavirus (MERS-CoV) in a cell-based infection assay.